Objective: To compare the long-term outcomes of surgical resection and radiofrequency ablation for the treatment of small hepatocellular carcinoma (HCC). Summary Background Data: Radiofrequency ablation (RFA) is a promising, emerging therapy for small HCC. Whether it is as effective as surgical resection (RES) for long-term outcomes is still indefinite. Methods: Two hundred thirty HCC patients who met the Milan criteria and were suitable to be treated by either RES or RFA entered into a randomized controlled trial. The patients were regularly followed up after treatment for 5 years (except for those who died). The primary end point was overall survival; the secondary end points were recurrence-free survival, overall recurrence, and early-stage recurrence. Results: The 1-, 2-, 3-, 4-and 5-year overall survival rates for the RFA group and the RES group were 86.96%, 76.52%, 69.57%, 66.09%, 54.78% and 98.26%, 96.52%, 92.17%, 82.60%, 75.65%, respectively. The corresponding recurrence-free survival rates for the 2 groups were 81.74%, 59.13%, 46.08%, 33.91%, 28.69% and 85.22%, 73.92%, 60.87%, 54.78%, 51.30%, respectively. Overall survival and recurrence-free survival were significantly lower in the RFA group than in the RES group (P = 0.001 and P = 0.017). The 1-, 2-, 3-, 4-, and 5-year overall recurrence rates were 16.52%, 38.26%, 49.57%, 59.13%, and 63.48% for the RFA group and 12.17%, 22.60%, 33.91%, 39.13%, and 41.74% for the RES group. The overall recurrence was higher in the RFA group than in the RES group (P = 0.024). Conclusions: Surgical resection may provide better survival and lower recurrence rates than RFA for patients with HCC to the Milan criteria.
H epatocellular carcinoma (HCC) is the sixth most common malignant tumor on earth. 1 It is prevalent in Asia and Africa, and increasing in the United States and Europe. 2, 3 For HCC conforming to the Milan criteria (single HCC ≤5 cm or up to 3 nodules <3 cm), theoretically the best treatment is liver transplantation. But the scarcity of donors limits this treatment. Thus, surgical resection (RES) is still considered trustworthy. 4 In the last 2 decades, local ablative therapies have started to become safe and effective for small HCC; of them, radiofrequency ablation (RFA) has been considered the most promising one. 5 On the one hand, a less than 2% treatment-related mortality and 5-year survival of 40%-70% can be achieved in RESs for HCC by experienced surgeons. [6] [7] [8] On the other hand, RFA shows encouraging results in treating HCC, and fewer invasions, shorter hospitalized time, and less expense can be expected. Most reports about RFA focus on the evaluation of the percentage of success in terms of tumor necrosis but few ascertain the long-term survival of the patients and recurrence of HCC. [9] [10] [11] [12] [13] To respond to the suggestion given in a recent study, 5 we conducted this prospective randomized trial to compare the long-term outcomes of RFA and RES for the treatment of small HCC.
METHODS

Diagnostic Criteria, Inclusion and Exclusion Criteria
Our diagnosis of HCC was according to (1) the cytohistological evidence or (2) the diagnostic criteria for HCC in the absence of biopsy used by the European Association for the Study of the Liver. 14 Because of the specific complication of cancer cell seeding, 15, 16 percutaneous liver biopsy was not suggested in our center. In this study, making a diagnosis of HCC without biopsy evidence mainly depended on radiological imaging techniques: ultrasonography, spiral computed tomography (CT), magnetic resonance imaging (MRI), and hepatic digital subtraction angiography (DSA).
1. When a tumor >2 cm was found in a noncirrhotic or cirrhotic liver, (a) the classical dynamic radiological features of HCC (contrast uptake in the arterial phase and rapid wash-out in the venous/late phase) were represented in 2 imaging techniques, or (b) 1 radiologic imaging technique showed typical features of HCC with an elevated α-fetoprotein (AFP) level >400 ng/mL. The diagnosis could be made when (a) or (b) was met. 2. When a tumor ≤2 cm was found in a noncirrhotic liver, the evidence of 2 radiologic imaging techniques was needed to make the diagnosis. In this circumstance, we preferred contrasted MRI rather than spiral CT for its superiority in discrimination. Hepatic DSA was another option when evidence could not be clearly achieved with other radiologic techniques. Elevation of AFP and the background of hepatitis B or C virus (HBV/HCV) infection were also considered supplemental when making diagnosis. 3. When a tumor ≤2 cm was found in a cirrhotic liver, MRI and hepatic DSA evidence were both necessary in making a diagnosis.
Other radiologic methods, elevation of AFP, and the background of HBV/HCV infection were also considered supplemental. 
Study Design
This study was to ascertain the hypothesis that RES was superior to RFA for the treatment of small HCC. We set overall survival as the primary end point, and recurrence-free survival and overall recurrence as secondary end points. Incidence of adverse events and length of hospitalization were also compared. Because of the nature of the interventions, the double-blind technique was not used. The protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the Clinical Trial Ethics Committee of West China Hospital, Sichuan University. This trial was registered at the Chinese Clinical Trial Register (ChiCTR-TRC-00000372). Informed consent was obtained from each recruited patient.
Sample Size
We used a 5-year overall survival rate after treatment to be the outcome measurement to estimate the sample size. According to our past data, we estimated that the 5-year overall survival rate would be 60% with RES and 40% with RFA.
A sample size of at least 115 patients in each group was calculated to be needed to detect a difference at 5% type-I error and 80% power for a 2-tailed log-rank test with 15% of patients supposed to be lost to follow-up.
Enrollment and Assignment
All patients diagnosed as having HCC and hospitalized in our center were candidates for enrollment. Once the patient met the inclusion criteria, information about this study was given by the physicians. Written informed consent was necessary when the patient was willing to take part.
From March 2003 to January 2005, the required 230 patients took part in the trial. A statistician from the registry center assigned them to 2 groups (the RFA group and the RES group) beforehand by a blocking/stratification randomization method with a computer (Table 1 ). The registry numbers for patients were printed on envelopes in order, and the corresponding group name was sealed in each envelope. Physicians received the envelope for each patient in the registry sequence kept in a container given by the statistician and kept by the chief nurse of our center. With the patient's personal data filled in, the envelope was unsealed the day before the treatment, and the patient was then informed about the specific intervention. The randomized sequence of intervention was only known by the statistician.
Follow-Up
Patients were required to come back to our center for a visit every 3 months for 60 months after treatment, except those who expired, lost contact, or quit. At least 3 phone numbers for each patient (or relatives) were required to be given to us. We scheduled visits through them. Serum AFP was measured; ultrasonography and helical CT were performed each visit. When intrahepatic recurrence was hard to ascertain, MRI or contrast-enhanced ultrasonography were performed. When extrahepatic recurrence was suspected, chest CT and bone scintigraphy were done. Once the recurrence was confirmed, the second-time treatment suggestion was proposed according to a decision of a multidisciplinary team of doctors including surgeons, pathologists, and radiologists; however, the patient's opinion was conclusive. The therapies were RFA, percutaneous ethanol injection, RES, transcatheter hepatic arterial chemoembolization and chemotherapy, and liver transplantation. All examinations and treatments were done in our hospital.
Statistical Analysis
The data of patients who were lost to follow-up or quit were treated as censored. Differences between the 2 groups were analyzed by the unpaired t test for continuous variables, and the categorical variables were analyzed by the χ 2 test or continuity correction method. The overall survival curves, recurrence-free survival curves, and overall recurrence curves were generated by the Kaplan-Meier method and compared by log-rank test. The relative prognostic significance of the variables in predicting overall survival and overall recurrence were assessed by univariate and multivariate Cox proportional hazards regression models. All variables with a P value <0.05 by univariate comparison were subjected to the multivariate analysis.
Results of the multivariate analysis were presented as relative risk (RR) with a corresponding 95% confidence interval (CI). All statistical tests were 2-sided, and a significant difference was considered when P <0.05. The statistical analyses of the data were performed using the SPSS 13.0 statistical software. All analyses were done on the intention-to-treat basis.
Radiofrequency Ablation
Procedure
We treated our patients with RFA by using a commercially available system (Radionics, Cool-Tip System, Burlington, MA USA) and a needle electrode with a 2-or 3-cm exposed tip and with ultrasound guidance (Vivid4, GE, USA). The percutaneous RFA procedure was as follows: After general anesthesia, grounding was achieved by 2 pads attached to the patient's thighs. The electrode was inserted through the tumor under ultrasound guidance. Because microbubbles were produced during the ablation, which may interrupt the accuracy of intraoperative ultrasonography (IOUS), the needle tip was required to reach the bottom (distal border) of the tumor in the first session. Thus, the ultrasound wave would not meet the microbubble area between nonablated lesion and transducer during the session of ablation. A safety margin from the distal border could be made in this way. This strategy was also useful in the insertion of the rest session(s). The ablation subsequence was always from bottom to top to provide a clearly real-time ultrasound monitoring. The electrode was needed to be inserted in different sites, and the ablation was performed repeatedly until the entire lesion was enveloped by assumed necrotic volumes. The total ablative area was required 0.5-1 cm over the tumor edge. When the electrode was in position, the system was switched to the impedance mode. After measurement of the baseline impedance, generator output power was gradually increased from 80 W to 200 W, with a peristaltic pump infusing cold saline into the electrode lumen to maintain the tip temperature below 20
• C. The timer was usually set to 12 minutes for each session. Impedance was monitored by the system synchronously. Sessions in the same site were repeated until impedance increased at least 10 over baseline and became stabilized. The electrode was heated to 90 to 100
• C before drawing back to eliminate seeding cancer cells and prevent bleeding. Treatment continued until complete ablation features were achieved in IOUS. An enhanced spiral CT was performed the second day after treatment. If any possible undestroyed lesions remained, the treatment 
Radiofrequency Ablation in Dangerous Locations
Hepatocellular carcinoma in dangerous locations 17 was defined as lesions ≤0.5 cm near large vessels, such as a primary or secondary branch of the portal vein, the base of hepatic veins, or the inferior vena cava, with lesions near extrahepatic organs <0.5 cm measured on radiological images. The route of electrode insertion was carefully considered on ultrasound scrutiny. When the tumor was in segment VII, close to the diaphragm (2 patients), the procedures were performed through their right pleural cavities. Saline was infused in the right pleural cavity to compress the right lobe of the lung, then, under ultrasound guidance, the electrode reached the target, and ablation was achieved through an artificial serothorax. A thoracic close drainage was needed for 2 days after therapy. When the tumors were located near subhepatic inferior vena cava or gastrointestinal tract (2 patients), we chose a laparoscopic approach. The ablation time was irregular in dangerous locations; ablation needed to be stopped as soon as the ultrasound detected microbubbles generated by ablation reaching the distal border of the assumed area. An experienced operator could manage most injuries to adjacent organs and structures and the heat sink effect from large vessels through this technique. All procedures in this study were performed by 2 experienced physicians, each with more than 1000 RFA experiences.
Surgical Resection
Surgical resection was carried out under general anesthesia. We performed anatomic partial hepatectomy with a resection margin of at least 1 cm over the tumor. The right subcostal incision with a midline extension was chosen. Anatomical partial hepatectomy was based on IOUS guidance. Intraoperative ultrasonography was routinely performed to estimate the number, size, location, and feeding vessels of the tumor, as well as to give an accurate vascular map of liver anatomy. According to the ultrasound, a marginal line and the main projection of the feeding vessels was marked with an electronic scalpel on the liver surface. Resection was focused on the ental border of the resection zone according to the vessels' projection instead of traditionally from the periphery. Thus, the feeding vessels could be exposed and ligated initially. A completely anatomic resection could be performed according to an area of discoloration after ligation. The risk of hemorrhage with this technique could be managed by extensive dissociation of the liver and subtle procedure. The Cavitron ultrasonic aspiration (CUSA, Valleylab Corp, USA) or water dissector (Jet2, Erbe Corp, Germany) was used to dissect the liver tissue, and hemostasis was achieved with dipolar electric coagulation, argon unit, titanium clips, and suturing. The Pringle maneuver was usually prepared in case of markedly cirrhotic liver, with a clamp/unclamp time of 15 minutes/5 minutes policy, but it was not often used (28/122 
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RESULTS
From March 2003 to January 2005, HCC was diagnosed in 2317 patients in our hospital, of which 483 patients met the inclusion criteria. Of these, 249 patients refused to join, 4 were excluded, and 230 took part in the trial (Figure 1) . One hundred fifteen patients assigned in the RFA group and 115 patients in the RES group were all included in the intention-to-treat analysis for survival and recurrence. Baseline characteristics were not significantly different between the 2 groups (Table 1) , nor was the tumor location (Table 2 ), but there were differences in the solitary tumor size (the proportion of small tumor was smaller in the RES group than in the RFA group, 45/89 vs 57/84, P = 0.021). There were actually 122 patients who had received surgical resections. Thirty one of 122 patients were treated with segmentectomy; 64/122 patients received bisegmentectomy; 23/122 underwent hemihepatectomy; 3/122 were treated with trisectorectomy; and 1/122 received right lateral sectorectomy plus bisegmentectomy of segment II+III. One hundred twenty-one of 122 patients had all lesions removed. All of the patients treated by partial hepatectomy achieved at least a 1-cm tumor-free resection margin by visual estimation during operation, whereas the shortest width measured in inviable specimens were from 0.7 to 3.5 cm. For 122 patients treated by partial hepatectomy, there were 12 specimens poorly differentiated, 65 moderately differentiated, and 45 well differentiated. In seven of those 122 patients, microsatellites were found, 1/7 nest of tumor cells located in the resection margin; and 13/122 microvascular invasions were found in the specimens, 4/13 found within the resection margin. Of 108 RFA-treated patients, 54/108 had single lesion ≤3 cm, treatment sessions were 2.21 ± 0.37/lesion; 24/108 had solitary HCC >3 cm, but <5 cm, treatment sessions were 3.89 ± 0.51/lesion; 29 patients had 2 lesions, treatment sessions were 2.59 ± 0.23/lesion; and 1 had 3 lesions, treatment sessions were 3, 1, and 1, respectively. Seventeen patients had lesions in dangerous locations, and all of them had tumors completely ablated. Seventeen patients in the RFA group were found to have the tumor partially remaining by enhanced posttreatment CT and received additional procedures (2 times for 16, 3 times for 1) during the same hospital admission. The 108 RFA-treated patients all achieved complete ablation of the tumor assessed by radiology (necrosis zone totally enveloped the lesion without enhancement) before checking out. None quit the trial. All were visited until 5 years after treatment or death, except 25 lost to follow-up (18 in the RES group and 7 in the RFA group).
Protocol Violations
Seven patients in the RFA group withdrew their consent after interventions were exposed. They chose and were treated with RES. Focal nodular hyperplasia (FNH) was diagnosed in 1/7 by biopsy. Two patients in the RES group were confirmed as misdiagnosed by postoperative pathologic evidence that indicated FNH in 1 and hepatic echinococcosis in the other, respectively. There were 16/122 additional lesions found in 15 patients who had received surgery compared with preoperative estimation, 15 lesions by IOUS, and 1 by specimen anatomy. Thirteen of 16 lesions were considered satellites (within same segment of primary tumor), and 3/16 were considered metastasis (without same segment of primary tumor). Of the 15 patients, 4 were found with more than 3 lesions by IOUS. The newly found lesions were all removed by partial hepatectomy, except one <1-cm nodule that was left in segment VII of a left trisectorectomy patient and was ablated by ethanol injection. All mentioned above were kept in their groups for the intention-to-treat analysis.
Hospitalization Length, Mortality, and Adverse Events
The hospitalization length was significantly longer after RES (15.36 ± 4.21 days) than RFA (6.92 ± 3.46 days) (P <0.05).
There was no patient who expired within the same hospital admission, making the mortality rate 0% in both groups.
Adverse events were significantly more frequent in the RES group than in the RFA group (32/115 vs 5/115, P <0.05). Adverse events in the RES group were as follows: hepatic failure (1 case), refractory ascites (13), encapsulated effusion needing percutaneous drainage (5), bile leakage (9), postoperative bleeding (2), and gastrointestinal bleeding (2) . Adverse events in the RFA group were gastric perforation (1 case), procedure-related hemorrhage (2), malignant seeding (1), and hepatic infarction (1) . A continual fever of 38.5
• C or higher for 3 days was encountered in 19 of RES group and 4 of the RFA group (19/115 vs 4/115, P <0.05). There were significantly more patients requiring analgesics after treatment in the RES group than in the RFA group (89/115 vs 13/115, P <0.05).
FIGURE 2.
Overall survival in 230 eligible patients, according to the treatment group. The 5-year overall survival rate was 75.65% in surgical resection group, whereas 54.78% in the radiofrequency ablation group.
FIGURE 3.
Recurrence-free survival in 230 eligible patients, according to the treatment group. The 5-year recurrence-free survival rate was 51.30% in surgical resection group, whereas 28.69% in the radiofrequency ablation group.
Survival
The median follow-up time was 3.1 years (0.5-5 years) in the RFA group and 3.87 years (0.1-5 years) in the RES group. Fifty-two patients in the RFA group died during the follow-up; causes of death were cancer recurrence (43), liver failure (6), upper gastrointestinal hemorrhage (1), and miscellaneous (2). Twenty-eight patients in the RES group died during the follow-up; causes were cancer recurrence (20 cases), liver failure (3), and miscellaneous (5).
The 1-, 2-, 3-, 4-, and 5-year overall survival rates for the RFA group and the RES group were 86.96%, 76.52%, 69.57%, 66.09%, 54.78% and 98.26%, 96.52%, 92.17%, 82.60%, 75.65%, respectively. The corresponding recurrence-free survival rates for the 2 groups were 81.74%, 59.13%, 46.08%, 33.91%, 28.69% for the RFA group and 85.22%, 73.92%, 60.87%, 54.78%, 51.30% for the RES group. Overall survival and recurrence-free survival were significantly higher in the RES group than in the RFA group (Figure 2 , Figure 3 , P = 0.001, P = 0.017).
Subgroup analyses of overall survival were performed in (1) solitary HCC ≤3 cm, (2) 3 cm < solitary HCC <5 cm, (3) multifocal HCC <3 cm, and (4) cirrhotic patients. Details can be found in Table 3 . Significant differences of RES's superiority in survival were shown in all subgroups (Figures 4-7: P = 0.030; P = 0.046; P = 0.042; P = 0.005) Besides intervention, 3 of 13 variables were also relevant to overall survival univariate analysis (Table 4) 
Recurrence
Recurrence was found in 73 patients treated with RFA and in 48 treated with RES. Details can be found in Table 5 .
Overall recurrence rate was significantly higher in the RFA group than in the RES group by intention-to-treat analysis (73 vs 48, P = 0.001) and by actual intervention analysis (69 vs 52, P = 0.002) ( Table 5 ). Early-stage recurrence (<2 years) was significantly higher in the RFA group than in the RES group (44 vs 26 / 42 vs 28, P = 0.010 / 0.045). No statistical difference was found in recurrence location (P = 0.815/0.959).
The 1-, 2-, 3-, 4-, and 5-year overall recurrence rates were 16.52%, 38.26%, 49.57%, 59.13%, 63.48% for the RFA group and 12.17%, 22.60%, 33.91%, 39.13%, 41.74% for the RES group, respectively. The overall recurrence was significantly higher in the RFA group than in the RES group (P = 0.024, Figure 8 ).
Five of 13 variables were related to overall recurrence univariate analysis (Table 4) 
DISCUSSION
This study demonstrated that in addition to liver transplantation, RES may provide better survival and lower recurrence than RFA for those patients with HCC conforming to the Milan criteria according to this trial.
According to the outcomes, cancer recurrence was the main reason for death in both groups (43/52 for RFA, 20/28 for RES). Hence, this result probably could be explained by the difference between the tumor clearances of the 2 therapies. HCC mainly disseminates through portal and hepatic veins. The microdissemination can invade the tributaries of the portal branches and shed tumor emboli in the neighboring branches of the same liver segment. [18] [19] [20] [21] Segmentbased anatomic partial hepatectomy removes at least 1 cm of the rim of normal liver parenchyma together with the original tumor and thus eradicates both the primary tumor and venous tumor thrombi. 22, 23 In the RFA procedure, when treating tumors larger than a single session ablative area, repeat insertions and ablations are needed. It is hard to overlay every ablative area precisely in the 3-dimensional liver with guidance of 2-dimensional ultrasonography. That may explain why it has been reported that intact nests of viable tumor cells can be found within an extensively necrotic HCC specimen after RFA. 24 Moreover, whether RFA induces tumor dissemination 25, 26 remains unclear. Because it has been reported that the best effect of local ablation may be achieved in tumors no more than 3 cm in diameter, 27, 28 we divided patients in the study into 3 subgroups: (1) solitary HCC ≤3 cm, (2) 3 cm < solitary HCC <5 cm, and (3) multifocal HCC <3 cm. Survival analysis showed significant differences in RES's superiority in all subgroups (P = 0.030; P = 0.046; P = 0.042), although the nature of different subgroups may affect their prognoses (Table 3 , Figure 4-6) , and the sample size was small. In subgroup of cirrhotic patients, the results echoed the conclusion above (Table 3 , Figure 7 ).
The overall recurrence rate and early-stage recurrence rate (<2 years) were both significantly higher in the RFA group than in the RES group (Figure 2 ). Sixty to 70% of recurrences correspond to intrahepatic metastases (true recurrences), whereas 30%-40% to de novo. True recurrences characteristically appear within 2 years, whereas de novo HCCs usually occur later than 2 years. 4 Because the anatomic partial hepatectomy is based on sound oncologic principles, 29 it seems to provide better tumor clearance, especially with the micrometastases. That may explain previous outcomes. No statistical difference was found in recurrence location (P = 0.815/0.959).This may be because of the sample size.
The reported 5-year overall survival rate of RFA is 41%-55.4%. [30] [31] [32] [33] [34] In this study, the 5-year overall survival rate of RFA was 54.78% and of RES was 75.65%. Both were higher than we estimated based on our previously gathered data. This may be because a large proportion of lost-to-follow-up patients existed in our prior data, and the database included patients treated by physicians with diverse experiences. 
